In this context, it has become necessary to evaluate the diagnostic utility of HER2 assays with respect to the detection of not only HER2-positive (IHC 3 + and/or amplified) but also HER2-low (IHC 2 + or IHC 1 + , non-amplified) BC cases. This evidence concerns the gene ERBB2 and breast cancer.